Key Takeaways:
Krystal Biotech, Inc. (NASDAQ: KRYS) reported first-quarter earnings of $1.83 per diluted share, significantly surpassing the Zacks Consensus Estimate of $1.45 and increasing from $1.20 in the same period last year.
"Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK," said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech.
The positive results were driven by strong sales of the company's flagship product, VYJUVEK, for the treatment of Dystrophic Epidermolysis Bullosa (DEB). Net product revenue for the quarter was $116.4 million, a 32 percent increase from the $88.2 million recorded in the first quarter of 2025. The company reported a gross margin of 95 percent.
The company's strong performance provides a solid foundation for its extensive clinical development pipeline. Krystal ended the quarter with $1.0 billion in cash, cash equivalents, and investments. The company issued full-year 2026 non-GAAP guidance for combined research and development and selling, general, and administrative expenses in the range of $175.0 million to $195.0 million.
Krystal provided updates on several key programs, highlighting regulatory and clinical progress. The U.S. Food and Drug Administration granted platform technology designation to two candidates: KB407 for cystic fibrosis and KB111 for Hailey-Hailey disease. This designation could shorten review cycles for future products using the same viral vector technology.
Enrollment is now complete for the registrational study of KB803 for corneal abrasions in DEB patients, with top-line results expected in the fourth quarter of 2026. The company also expects to report data from its EMERALD-1 study of KB801 for neurotrophic keratitis before the end of the year.
The robust sales growth for VYJUVEK demonstrates successful commercial execution and market adoption. Investors will be watching for the upcoming data readouts in the second half of 2026, which represent the next major catalysts for the company's pipeline.
This article is for informational purposes only and does not constitute investment advice.
